Tags: Cancer | prostate | drug | succeeds | trial | Pfizer

Prostate Cancer Drug Succeeds in Key Trial

Image: Prostate Cancer Drug Succeeds in Key Trial
(Copyright iStock)

Thursday, 14 Sep 2017 09:09 AM

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in global sales of $141 million in the second quarter.

An approval to treat non-metastatic CRPC would significantly boost sales of Xtandi, which Pfizer got access to when it bought Medivation for $14 billion last year. Astellas owns the rights to sell Xtandi outside the United States.

Pfizer said on Thursday that Xtandi, in combination with an anti-hormone therapy, was statistically significant in improving survival rate in men with non-metastatic CRPC without their cancer spreading, when compared with the standalone anti-hormone therapy.

Patients with CRPC experience cancer progression despite androgen deprivation therapy, a treatment that blocks the production of the hormone.

Pfizer is pinning its growth on the success and approvals of 15 drugs over the next five years, a list that includes Xtandi and breast cancer drug Ibrance.

Earlier this month, the U.S. Food and Drug Administration approved Pfizer's Mylotarg for certain patients with acute myeloid leukemia, re-clearing a drug that had been pulled off the market in 2010.

Prostate cancer a big market for drugmakers. More than 161,000 men are estimated to be diagnosed with prostate cancer in 2017 in the United States, according to the American Cancer Society.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease. The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) -...
prostate, drug, succeeds, trial, Pfizer
250
2017-09-14
Thursday, 14 Sep 2017 09:09 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved